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Abstract 
The insulin-like growth factor binding proteins (IGFBPs) comprise a family of six distinct proteins which modulate insulin-like 
growth factor action. We have isolated cDNAs encoding the six mouse IGFBPs (mlGFBPs). In addition, we studied the mRNA 
expression of the six mlGFBPs during development and in various adult tissues. Our results show that each of the six mlGFBPs is 
highly homologous to their human and rat counterparts, whereas only the N and C terminal ends are conserved between the six 
mlGFBPs. Northern blotting revealed that mlGFBP-2, -3, -4 and -5 genes are already expressed at gestational day 11.5, suggesting a 
role for these mlGFBPs in embryonal development. In liver, a peak of mlGFBP-1 mRNA expression was found around birth, 
suggesting a function for mlGFBP-1 in the newborn mouse. Finally, tissue-specific expression of the six mouse IGFBP genes was 
observed inadult tissues uggesting different roles or modes of actions in adult life. 
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1. Introduction 
Insulin-like growth factors (IGFs) are peptides displaying 
important functions in regulating cell proliferation, differ- 
entiation and metabolism (Sara and Hall, 1990). The IGFs 
are synthesized and secreted by many tissues and interact 
with the cell by binding to specific membrane receptors 
(Rosenfeld and Hintz, 1986; Daughaday and Rotwein, 
1989). In the body fluids, the IGFs are found in complex 
with a specific group of proteins, the IGF binding proteins 
(IGFBPs). These IGFBPs have an affinity for IGFs equal 
to that of IGF-receptors and are involved in the modula- 
tion of IGF action in different issues (Hardouin et al., 
1987; Baxter and Martin, 1989). The IGFBPs belong to a 
family of at least six different proteins, designated 
IGFBP-1 to -6. At present, the cDNAs encoding the six 
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rat and human IGFBPs have been isolated and character- 
ized revealing that the six IGFBPs are clearly distinct, but 
share regions with strong homology (Drop et al., 1992). 
Furthermore, IGFBP gene expression is tissue specific 
and developmentally regulated (Rechler and Brown, 
1992). 
Proposed roles of the IGFBPs are to distribute the 
IGFs over the various body fluid compartments and to 
protect he body from the hypoglycemic effects of IGFs. 
Another function of the IGFBPs appears to be the modu- 
lation of IGF binding to their receptors, thereby playing 
an important role in mediating IGF action (Clemmons, 
1992). However, the precise role of the six different 
IGFBPs is still poorly understood. Using in situ hybridi- 
zation techniques, we have shown recently that the six 
mouse IGFBPs are expressed in a tissue and cell specific 
manner during development, suggesting distinct roles for 
the six mouse IGFBPs in embryonal and fetal life 
(Schuller et al., 1993). Here we describe the isolation and 
characterization of the cDNAs encoding the six mouse 
IGFBPs. We have studied the mRNA expression of the 
six mouse IGFBPs during the second half of gestation and 
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postnatally by examining total RNA extracted from whole 
conceptuses (day 11-18) and from pre- and postnatal 
liver. In addition, we determined the mRNA expression i
various adult mice tissues. 
2.3. Quantification of blots 
Autoradiograms were quantified by densitometric 
scanning using a Bio-Rad video densitometer model 620. 
2. Materials and methods 3. Results 
2.1. Isolation of cDNA clones 3.1. Isolation of mlGFBP cDNA clones 
For isolation of mouse IGFBP-1 cDNA clones, 
1 × 106 phage plaques of a liver cDNA library in lambda 
gtl 1 (Promega, Madison, WI) were lifted onto nitrocellu- 
lose filters and hybridized with a 32p-labelled Pstl-Xbal 
(490 bp) fragment of a human IGFBP-1 cDNA clone, p19 
(Brinkman et al., 1988) at 59°C according to standard 
procedures (Maniatis et al., 1982). For isolation of the 
cDNAs encoding mouse IGFBP-2, -3, -4, -5 and -6, 
mouse liver and kidney cDNA libraries in lambda gtl 1 
and a mouse liver cDNA library in lambda zap (kindly 
provided by Dr. F. van Leuven, University of Leuven, 
Belgium) were screened. Complementary DNA fragments 
specific for each of the IGFBPs were amplified by PCR as 
described before (Schuller et al., 1993), 32p-labelled and 
used as probe at 65°C. After washing, filters were ex- 
posed to X-ray film with an intensifying screen at -80°C 
for 3 days. Positive phage plaques were purified by re- 
screening and DNA isolated according to standard proce- 
dures (Maniatis et al., 1982). All cDNA inserts were ex- 
cised with EcoR1/Notl, inserted into pBluescript KS + 
(Stratagene) and sequenced according to the dideoxy 
chain termination method (Sanger et al., 1977) using the 
M13 forward and reverse primers or specifically designed 
oligonucleotide primers, synthesized on a DNA synthe- 
sizer (Applied Biosystems). 
2.2. Northern analysis 
Tissues (liver, kidney, lung, heart, spleen, brain, mus- 
cle, testis and ovary) were obtained from adult BALB/c 
mice, frozen in liquid nitrogen and stored at-80°C until 
use. Likewise, mouse conceptuses (11-18 days gestation) 
were frozen in liquid nitrogen and stored. In addition, 
liver was isolated from 16- and 18-day-old mouse fetuses 
and from mice 1, 3, 7, 14 and 28 days postnatally. Total 
RNA was extracted by the guanidinium thiocyanate 
method as described by Chomczynski and Sacchi (1989). 
RNA was denatured with dimethylsulfoxide and glyoxal, 
electrophoresed in 1% agarose and transferred to nylon 
membranes (GeneScreen, Du Pont de Nemours, Ger- 
many). Hybridization was performed with 32p-labelled 
mlGFBP cDNA fragments at 42°C in a RNA hybridiza- 
tion buffer containing 50% formamide, 10% dextran 
sulphate, 100/zg/ml ssDNA, 10× Denhardt's, 0.1% 
Na4P207, 50 mM Tris (pH 7.5) and 0.1% SDS. 
Screening of mouse liver and kidney cDNA libraries 
using IGFBP specific probes resulted in the isolation of 
several independent clones. Sequencing of the inserts and 
comparison of the nucleotide sequence with that of the six 
rat IGFBPs revealed that we had isolated several cDNA 
clones for each of the six mouse IGFBPs. Furthermore, 
for all six mouse IGFBPs, at least one complete cDNA 
was isolated. The nucleotide sequences and predicted 
amino acid sequences of the six mouse IGFBP cDNAs are 
shown in Fig. 1. Comparison of the amino acid sequence 
of the six mouse IGFBPs showed conservation of 18 cys- 
teine residues in all mlGFBPs, with the exception of 
mlGFBP-4 which has two additional cysteines and 
mlGFBP-6 which only contained 16 cysteine residues. 
Furthermore, a high degree of homology between the six 
mlGFBPs was observed in both the N-terminal and C- 
terminal regions, whereas the middle part of the IGFBPs 
is less well conserved. Both mlGFBP-1 and -2 contain an 
Arg-Gly-Asp sequence at their C-terminal end (Fig. 2). 
Comparison of the predicted amino acid sequences of 
mlGFBP-1, -2, -3, -4, -5 and -6 with the corresponding 
human IGFBP showed a homology of 73%, 89%, 81%, 
93%, 97% and 73%, respectively. The predicted amino 
acid sequences showed an even higher degree of homol- 
ogy with the rat IGFBPs (94%, 96%, 93%, 99%, 99.6% 
and 94%, respectively). In mIGFBP-2, an additional gly- 
cine at position 118 was found and mlGFBP-3 lacked an 
alanine at position 7, when comparing them with their 
respective rat counterparts (Margot et al., 1989; Shi- 
masaki et al., 1989). Furthermore, mlGFBP-6 has an in- 
sertion of 9 amino acids (residues 14-22), which is not 
found in rat IGFBP-6 (Shimasaki et al., 1991) (Fig. 2). 
3.2. Developmental m GFBP mRNA expression 
The mRNA expression of the six mlGFBP genes dur- 
ing development was examined in total RNA extracted 
from whole conceptuses (11-18 days gestation) and in 
total RNA extracted from pre- and postnatal liver. As is 
shown in Fig. 3, mRNA expression of mlGFBP-2, -3, -4 
and -5 was already detectable in embryos at day 11.5 Ex- 
pression of mIGFBP-1 mRNA was hardly detectable and 
first seen in 13.5 day embryos (not shown). Transcripts 
for mlGFBP-6 were not detected even after an exposure 
time of 2 weeks (not shown). 
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Fig. 3. Messenger RNA expression of mlGFBP-2, -3, -4 and -5 in total 
RNA isolated from mouse embryos. RNA (20/~g) was applied to each 
lane. The RNA samples were obtained from embryos at 10.5 (lane 1), 
12.5 (lane 2), 13.5 (lane 3) and 14.5 (lane 4) days of gestation. 
Fig 4. (a) Messenger RNA expression of mIGFBP-1, -2, -3 and -4 in 
fetal and postnatal mouse liver. In each lane 20/tg of total RNA was 
applied isolated from 18 day fetal liver (18) and from liver obtained 1, 
3, 7, 14 and 28 days after birth (1, 3, 7, 14 and 28, respectively). 
In total RNA extracted from fetal and postnatal livers 
(Fig 4a), expression of mlGFBP-1 was detectable at day 
16.5 of gestation and showed a dramatic increase at the 
first day after birth. Expression of mlGFBP-1 was still 
high at day 3 postnatally, but decreased to lower levels 
thereafter. Expression of mlGFBP-2  was also detectable 
in fetal livers and increased dramatically after birth. How- 
ever, the xpression of mIGFBP-2 decreased only slightly 
after postnatal day 3 and remained abundant hereafter. 
Expression of mlGFBP-3 transcripts was observed from 
day 18.5 of gestation. The levels of mlGFBP-3 mRNA 
expression slowly increased to a max imum at 1 week 
postnatally. Expression of mlGFBP-4  was observed from 
fetal day 16.5 and did not change dramatically over the 
period examined. An interpretation of these results based 
on densitometric measurements is given in Fig. 4b. Ex- 
pression of mlGFBP-5 and -6 mRNA was not observed, 
even after an exposure time of 2 weeks. Finally, fl-actin 
mRNA expression was found to decrease after birth. This 
observation has also been made during brain development 
in mouse (Lazarini et al., 1991), demonstrating that fl- 
actin expression cannot always be used to show equality 
of the amount of RNA applied. 
3.3. Tissue specific mlGFBP mRNA expression in adult 
mice 
Total RNA from different organs of adult BALB/c 
mice was examined for IGFBP gene expression by North- 
ern blot analysis. A summary of these results i  given in 
Table 1. Expression of IGFBP-1 was detected solely in 
liver. High expression of mlGFBP-2  was found in liver, 
but also in kidney, lung, brain, spleen, testis and ovary. 
Transcripts for mlGFBP-3 were detected mainly in kid- 
ney, liver, lung, heart, spleen and muscle. Expression of 
mlGFBP-4 was highest in liver, kidney and spleen, but 
also detectable in lung, heart, brain and muscle. Expres- 
sion of mlGFBP-5 was abundant in kidney, muscle and 
Table 1 
Messenger RNA expression of the six mlGFBPs in adult mouse tissues 
IG~P-1 IG~P-2 IG~P-3 IG~P-4 IG~P-5 IG~P-6 
Liver + ++ + ++ - +/- 
Kidney - ++ ++ ++ ++ - 
Lung - + + + + + 
Heart - +l- + + + + 
Spleen - + + ++ +/- +/- 
Brain - + +/- + + +/- 
Muscle - - + + ++ + 
Testis - + - - + + 
Ovary - + +/- - ++ + 
+, detected; -, not detected; 4-/-, only detected after an exposure time of >10 days. 
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Fig. 4. (b) Relative hybridization of mIGFBP-1, -2, -3 and -4 based on densitometric measurements. Highest mRNA level of each mIGFBP in liver was 
set to 100%. Results are presented as a percentage of the maximum expression level. 18 fl represents 18 days fetal liver; 1, 3, 7, 14 and 28 pl represent 
1, 3, 7, 14 and 28 days postnatal liver. 
ovary, being lower in lung, heart, brain and testis, 
whereas mlGFBP-6 was expressed mainly in lung, heart, 
muscle, ovary and testis (Table 1). 
4. Discussion 
Our data show that the six mlGFBPs are highly homo- 
logous in both the C-terminal and N-terminal region. 
Furthermore, 18 cysteine residues were found spatially 
conserved in all mlGFBPs, with the exception of 
mlGFBP-4 which has two additional cysteines and 
mlGFBP-6 which lacks two cysteine residues. Thus, we 
conclude that the distribution of the cysteine residues in 
the mlGFBPs is completely analogous to that of the hu- 
man IGFBPs (Drop et al., 1992). In addition, every 
murine IGFBP is highly homologous to its human and rat 
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counterpart. This also holds true for the central part of the 
IGFBPs where no obvious conservation is found between 
different IGFBPs from one species. In relation to the 
functions of the mlGFBPs, these observations may indi- 
cate that the N- and C- terminal regions contain domains 
important for all six mlGFBPs, for instance binding of 
IGF, whereas the middle part may represent a region that 
is important for the unique features of each of the 
mlGFBPs, such as cell specific attachment, sensitivity 
to proteases and protein interactions. Recently, the isola- 
tion of a mlGFBP-2 genomic clone has been reported 
(Landwehr et al., 1993). The predicted amino acid se- 
quence of this clone was identical to the mlGFBP-2 
cDNA clone reported here, with the one exception being a 
His residue at position 99, where we found an Asp resi- 
due. Whether this difference represents a cloning artefact 
or a natural polymorphism remains to be investigated. 
In whole embryos, transcripts for mlGFBP-2, -3, -4 
and -5 were already detectable at 11.5 days gestation, 
whereas low levels of mlGFBP-1 mRNA were first found 
in 13.5-day-old embryos and expression of mlGFBP-6 
was below detection limits. Using in situ hybridization, 
we have shown that mRNAs for mlGFBP-2, -4 and -5 are 
expressed in various tissues of mid-gestational mouse 
embryos and mRNA expression of mlGFBP-1 was de- 
tected in liver. Expression of the mlGFBP-3 and -6 genes 
was found in fetal stages (Schuller et al., 1993). Further- 
more, Cerro et al. (1993) recently showed by in situ hy- 
bridization techniques that IGFBP-1, -3, -4 and -6 were 
expressed at least as early as rat embryonic day 14. Our 
finding that mRNA expression of mlGFBP-6 was below 
detection limits in 20/zg total RNA extracted from whole 
embryos uggests that the mRNA expression of IGFBP-6 
observed in rat embryonal liver and a previously unrec- 
ognized cell population surrounding developing cartilage 
(Cerro et al., 1993) is either at a low level or that these 
ceils contribute to only a small percentage of the embryo 
and therefore the expression of mlGFBP-6 mRNA is not 
detectable in total RNA extracted from a whole embryo. 
Taken together, these observations indicate that all 
IGFBPs are expressed in mid-gestational embryos. 
Using gene disruption techniques, it has recently been 
shown that both IGF-I and IGF-II are essential for normal 
embryonic and fetal mouse development. Homozygous 
disruption of the IGF-I or IGF-II genes resulted in severe 
growth retardation (birth weight 60% of normal litter- 
mates). Double mutants carrying both disrupted IGF-I and 
IGF-II genes displayed an even more severe growth defi- 
ciency, reaching only 30% of the normal birth weight 
(DeChiara et al., 1990; Liu et al., 19.93). Comparison of 
embryonal growth kinetics revealed that the growth retar- 
dation induced by IGF-I gene disruption was first seen at 
embryonal day 13.5, whereas that induced by IGF-II dis- 
ruption was already seen at embryonal day 11.5 (Baker et 
al., 1993). Thus, these observations indicate that all six 
mlGFBP genes are expressed at the stage of development 
when IGF action is essential. Therefore, the IGFBPs may 
play a significant role in mediating the IGF effects in em- 
bryonal growth and development. 
In fetal and postnatal liver, a striking mRNA expres- 
sion pattern was observed for mlGFBP-1, being highest at 
days 1 and 3 after birth. Expression of mlGFBP-2 mRNA 
also increases after birth and decreases after postnatal day 
3, but the expression stays high thereafter. These findings 
confirm the observations of Babajko et al. (1993) who 
showed that the transcriptional ctivity of the rat IGFBP-1 
and -2 genes in liver are 25 times and 5 times greater at 
birth than at 16 days gestation. At birth, hepatic mRNA 
levels of rlGFBP-1 and -2 were increased approximately 
50-fold and 5-10-fold, decreasing to approximately 20% 
by day 6 for rlGFBP-1, whereas the levels of rlGFBP-2 
mRNA remained constant. These observations suggest a
distinct role for mlGFBP-1 produced by the liver during 
the first days after birth. A possible role for transiently 
high levels of IGFBP-1 in early postnatal life was sug- 
gested to be the modulation of the growth promoting ac- 
tivities of IGFs, prior to growth hormone sensitivity 
(Cerro et al., 1993). Although this possibility exists, tran- 
scripts for the growth hormone receptor have been de- 
tected at earlier stages in rat liver (Berry et al., 1993). 
Furthermore, mRNA of the growth hormone-responsive 
serpin gene Spi 2.1 is expressed in fetal rat liver. In addi- 
tion, the same deoxyribonuclease I hypersensitive sites 
were present in the 5' flanking region of the Spi 2.1 gene 
in DNA isolated from fetal and postnatal rat livers, sug- 
gesting that the gene is transcriptional competent in fetal 
life (Berry et al., 1993). Therefore, the possibility exists 
that the growth promoting effects of IGFs are also already 
under growth hormone control in late fetal and early 
postnatal life. Another possibility is that the high IGFBP- 
1 mRNA levels reflect he nutritional changes of the new- 
born mice, since for instance fasting has also been shown 
to induce both IGFBP-1 and -2 mRNA expression in rat 
liver (Murphy et al., 1990; Ooi et al., 1990; Orlowski et 
al., 1990). 
The mRNA expression of the six mlGFBP mRNAs in 
various adult mouse tissues, as studied by Northern blot- 
ting, revealed tissue specific expression patterns for each 
of the six mlGFBPs, which were partly overlapping, but 
distinct. In general, the mRNA expression patterns of the 
six mlGFBPs as described here, are in agreement with 
previous observations for the human and rat IGFBPs 
(Rechler and Brown, 1992), although additional sites of 
low IGFBP mRNA expression have been reported. 
In summary, we have isolated and characterized the 
cDNAs encoding the six mlGFBPs. Northern blotting 
revealed that mIGFBP-2, -3, -4 and -5 genes are already 
expressed at gestational day 11.5 and that at least five of 
the six mlGFBP genes are expressed at 13.5 days gesta- 
tion, suggesting roles for the IGFBPs in organogenesis 
and embryonal development. Furthermore, the peak in 
especially mlGFBP-1 mRNA expression found in liver 
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shortly after birth suggests an important role for this pro- 
tein in the newborn mouse. Finally, the tissue specific 
expression patterns of  the six mlGFBP genes in adult 
mice, suggest distinct roles or modes of  actions for the 
different mlGFBPs  in adult life. 
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